<DOC>
	<DOCNO>NCT01545388</DOCNO>
	<brief_summary>This study evaluate effect addition metformin daily ( q.d . ) twice daily ( b.i.d . ) sitagliptin monotherapy Japanese participant Type 2 diabetes mellitus ( T2DM ) inadequate glycemic control diet/exercise therapy sitagliptin monotherapy . The primary hypothesis addition metformin 250 mg b.i.d . metformin 500 mg q.d . superior addition placebo change baseline hemoglobin A1c ( HbA1c ) 24 week addition metformin 500 mg q.d . non-inferior addition metformin 250 mg b.i.d . change baseline HbA1c 24 week .</brief_summary>
	<brief_title>Metformin Add-on Regimen Comparison Study Japanese Participants With Type 2 Diabetes Mellitus ( MK-0431A-136 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 Diabetes Mellitus ( T2DM ) Currently treat diet/exercise stable dose sitagliptin ≥ 4 week , additional oral hypoglycemic agent ( AHA ) prior 8 week , HbA1c ≥ 6.0 % ≤ 9.0 % ; Currently treat diet/exercise stable dose sitagliptin ≥ 10 week , additional oral AHA prior 8 week , HbA1c ≥ 6.5 % &lt; 10.0 % Type 1 diabetes mellitus , Secondary diabetes mellitus , Gestational diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>